What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Patient Notes
Page 24 of 25 of this archive, newest first.
Page 24
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Randomised withdrawal is the cleanest design in this field and the least discussed
The regain trajectories, arm by arm, with the estimands named.
Two sessions a week, and the evidence behind the prescription
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
The ceiling is a tolerability finding, not an efficacy one
Where the curve flattens, what flattens with it, and what does not.
Turkey pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
A needle is a single-use instrument
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the cagrilintide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A guide to the results that will resolve themselves
Three different explanations for the same abnormal number, and how to tell them apart.
Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The arithmetic of a step: what doubling a dose actually asks of you
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
A guide to the results that will resolve themselves
Three different explanations for the same abnormal number, and how to tell them apart.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A guide to the results that will resolve themselves
The panel drawn during a week of vomiting is measuring the vomiting.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…